Compare QDEL & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | CDNA |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2022 | 2007 |
| Metric | QDEL | CDNA |
|---|---|---|
| Price | $11.06 | $20.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $28.25 | $28.00 |
| AVG Volume (30 Days) | ★ 3.0M | 742.5K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.35 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $2,730,200,000.00 | $48,324,000.00 |
| Revenue This Year | $3.51 | $16.01 |
| Revenue Next Year | $3.86 | $11.31 |
| P/E Ratio | ★ N/A | $428.60 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $9.92 | $10.96 |
| 52 Week High | $35.58 | $23.24 |
| Indicator | QDEL | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 52.61 |
| Support Level | $10.86 | $16.63 |
| Resistance Level | $12.85 | $21.20 |
| Average True Range (ATR) | 0.90 | 1.41 |
| MACD | 0.12 | -0.10 |
| Stochastic Oscillator | 40.78 | 51.65 |
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.